Evidence map›Paper›PMID 39627392›Full record

ReviewHypertension research : official journal of the Japanese Society of Hypertension2025

Current updates and future perspectives in uric acid research, 2024.

Masanari Kuwabara, Ryusuke Ae, Koki Kosami, Mehmet Kanbay, Ana Andres-Hernando, Ichiro Hisatome, Miguel A Lanaspa

Abstract readReview
In one paragraph

Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Cold-Adapted Uric Acid-DegradingMolecules (Basel, Switzerland) · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Masanari KuwabaraDivision of Public Health, Center for Community Medicine, Jichi Medical University, Tochigi, Japan. kuwamasa728@gmail.com.
Ryusuke AeDivision of Public Health, Center for Community Medicine, Jichi Medical University, Tochigi, Japan.
Koki KosamiDivision of Public Health, Center for Community Medicine, Jichi Medical University, Tochigi, Japan.
Mehmet KanbayDivision of Nephrology, Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.
Ana Andres-HernandoDivision of Endocrinology, Metabolism and Diabetes, School of Medicine, University of Colorado Denver, Aurora, CO, USA.
Ichiro HisatomeDepartment of Cardiology, NHO Yonago Medical Center, Tottori, Japan.
Miguel A LanaspaDivision of Endocrinology, Metabolism and Diabetes, School of Medicine, University of Colorado Denver, Aurora, CO, USA.

Funding

A Novel Role for Vasopressin in Fructose-Induced Metabolic SyndromeR01DK121496 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LANASPA GARCIA, MIGUEL ANGEL · 2020 to 2023
$1.6M
NIDDK NIH HHS R01 DK121496
6 · The paper itself

Abstract

Uric acid, the final product of purine metabolism, plays a significant role in hypertension Research on uric acid has advanced significantly, particularly regarding its links to hypertension and cardiovascular disease (CVD). Our 2023 review covered the relationship between uric acid, hypertension; and CVD, however, numerous new studies have emerged since then. This paper provides an update, summarizing recent findings over the past two years on hyperuricemia and its association with hypertension, preeclampsia, arteriosclerosis, kidney disease, sleep-disordered breathing, CVD, and so on. Hyperuricemia, often driven by reduced uric acid excretion or increased production, is influenced by genetic factors and lifestyle habits, including high-purine foods, alcohol, and fructose intake. While hyperuricemia has been proposed to contribute to hypertension and CVD through mechanisms like inflammasome activation and oxidative stress, its causal role remains debated. Further clinical and basic science studies on hyperuricemia and purine metabolism are necessary to clarify its impact on CVD and guide therapeutic approaches.

Indexed as

Cardiovascular DiseasesHypertensionHyperuricemiaUric AcidHumansUric Acidassociationcardiovascular diseasehyperuricemiapreeclampsiauric acid

Identifiers

PMID39627392
PMCPMC11798692

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.